REM-422

N/A

Report date: 2026/03/23 10:24:31

First In Class

Base Information

Drug NameREM-422

Drug Alias NameREM-422

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionRNA inhibitorsTranscriptional activator Myb inhibitors

TargetsRibonucleic AcidTranscriptional activator Myb

Therapy Area/IndicationsMyelodysplastic SyndromesCarcinoma, Adenoid CysticLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesFrance

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsMyelodysplastic SyndromesCarcinoma, Adenoid CysticLeukemia, Myeloid, Acute

Inactive IndicationsN/A

ATC CodeN/A